OnKure, Inc.
OnKure discovers and developes next generation Histone Deacetylase (HDAC) inhibitors for the treatment of various cancers and neuropathies.
Industry: Therapeutics
鈥婩unding Stage: Series B Round or beyond
The Insider E-Newsletter: Get the latest opportunities and events right in your inbox. Subscribe